Moderna, Inc. MRNA
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
The news check keeps the assessment current.
General analysis — not personal advice.
Existing positions can be maintained while new investors await further data.
Strong cash position, raised guidance and positive pipeline data are balanced against ongoing execution risk and concentration risk in COVID revenue, supporting a neutral signal.
The market reacts positively to the unexpected profit, raised forecasts and regulatory approvals.
HOLD is the call. Positive is the market mood. Medium risk means some things can go wrong.
Latest change
- 13 Nov 2026 — Report showed profit turnaround and raised guidance following Analyst Day.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (2) — follow the company freeAbout the company
Moderna develops and commercializes mRNA-based vaccines and therapies. The company has products including Spikevax for COVID-19, mRESVIA for RSV and a recently approved influenza vaccine. The pipeline includes personalized cancer vaccines in partnership with Merck as well as programs for norovirus and rare diseases.
Bull case
Raised revenue growth guidance, new approvals and phase 3 data for intismeran strengthen growth prospects.
Bear case
High valuation, continued dependence on COVID vaccines and uncertain commercial scaling of cancer vaccines limit upside.
Sensitivity analysis
| Factor | If it weakens | If it strengthens |
|---|---|---|
| intismeran phase 3 results | Failed regulatory discussions → delayed or no launch of cancer vaccine reduces diversification potential. | Successful regulatory path → broadened oncology portfolio and higher long-term revenue potential. |
| mFLUSIVA launch | Weak initial sales → continued reliance on COVID revenues and higher burn rate. | Strong adoption → faster revenue growth and improved profitability outlook. |
Why this signal
Strong cash position, raised guidance and positive pipeline data are balanced against ongoing execution risk and concentration risk in COVID revenue, supporting a neutral signal.
Recent news
Q3 report was published on 6 November with revenue of USD 1.3 billion, return to profit and raised revenue growth guidance to 15–25 percent for 2026. Analyst Day on 12 November confirmed phase 3 data for intismeran showing 42 percent lower risk of recurrence in melanoma plus combination vaccine approvals in Canada and EU. The stock fell about 14 percent after Analyst Day on profit taking.